Therapy ‘toolbox’ helps rescue poorly recovering patients at London maintenance clinic. by unknown
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From summary and commentary
A personalised psychosocial intervention
was trialled for opioid-dependent patients
being prescribed methadone or
buprenorphine on a maintenance basis but
who were still using heroin or cocaine.
Distinct from most other trials of additional
psychosocial therapies, instead of a set
programme, in this trial the interventions
were selected from a ‘toolbox’ to match
the patient’s needs and preferences and
adapted in the light of how they
responded.
Compared to usual treatment, among
patients randomly allocated to this
approach there were greater reductions in
heroin and cocaine use and improvements
in health-related quality of life, making the
interventions cost-effective according to
some accepted yardsticks. However, these
findings which emerged in relatively ideal
rather than typical circumstances.
This entry is our analysis of a study considered particularly relevant to improving
outcomes from drug or alcohol interventions in the UK. The original study was not
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Instead of a set programme, a clinic in London tried offering methadone or buprenorphine
patients still using heroin or cocaine a selection from a suite of well-supported psychological
interventions tailored to the patient and then systematically re-tailored in the light of how they
responded. It worked – but did it work well enough, and would the findings be replicated in more
typical circumstances?
SUMMARY Maintaining patients by prescribing the opioid medications methadone or
buprenorphine is the standard first-line treatment for opiate dependence in the UK. However,
many patients discontinue treatment, others do not take their medication as directed, continue
to use other opioids, or relapse to pre-treatment levels of opioid use. Cocaine use (particularly
use of crack cocaine) and co-occurring anxiety and mood disorders are common.
To address such issues supplementary psychosocial
interventions have extensively been trialled, but
with limited success. The UK’s National Institute for
Health and Care Excellence (NICE) endorses only
contingency management, behavioural couple and
family therapies, and 12-step-based groups, while
a review concluded that no psychosocial
intervention had been found to reliably enhance
the effectiveness of opioid maintenance
treatments.
However, these supplements have usually taken
the form of distinct, manual-driven therapies.
Following the manual, typically practitioners offer
patients a set progression of interventions,
affording little scope for tailoring treatment
according to patient preferences and adapting it to
how patients are doing.
In contrast, a personalised psychosocial
intervention was developed for the featured study.
Rather than a set programme, it drew on a ‘toolkit’
of techniques adapted from manuals and clinical
guidelines, at least two of which were selected for
each patient based on a ‘case formulation’. These
are developed during collaborative discussions
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which formulate a working hypothesis of how a disorder is being maintained, focusing on
cognitive, emotional, and interpersonal factors. These discussions are usually
supplemented by information gathered from standard assessment scales and clinical case
conferences. As treatment progresses, patients and therapists review progress, updating
the formulation and adapting therapeutic components as required. The featured study was
the first to trial such a strategy – common in mental health – in the context of opioid
maintenance treatment, specifically to help improve outcomes for patients not responding
as well as intended to treatment.
The site of the study was a specialist, publicly funded and provided community addictions
service in London. Researchers screened patients to find adults seeking to continue the
opioid maintenance they had been in for at least six weeks, who met criteria for opioid or
cocaine dependence over the past 12 months, and who were classified as ‘non-responders’
on the basis of interviews and urine tests revealing opioid or cocaine use in the past 28
days, indicating that the current treatment had failed to entirely suppress these forms of
illegal drug use. The question asked by the study was whether for these patients – the
bulk of patients in opioid maintenance in the UK – a personalised psychosocial
intervention added to usual treatment would prove more effective than usual treatment
alone. Primarily this was assessed by the proportion shown by interviews and urine tests
not to have used heroin or cocaine over the final four weeks of the 18–20 week trial and
therefore to have now become ‘responders’ to treatment. Missed tests were counted as
indicative of heroin and cocaine use. Also assessed was how much overall (ie, not just in
treatment costs, but in costs to society as a whole including crime) these gains cost, and
whether improvements in the patients’ quality of life were gained at below the cost
considered by NICE to be a cost-effective use of resources.
Patients who agreed to join the study were randomly assigned to treatment as usual or
this plus a personalised psychosocial intervention. They and their clinicians and research
staff knew who had been allocated to which. Patients assigned to the intervention were
first assessed by a clinical psychologist and an assistant psychologist to agree a case
formulation and intervention plan. The extensive measures of psychological health made
by the researchers for the purpose of the study were fed into the assessment. Weekly
case conferences reviewed the treatment plans.
Intended to be delivered over 12 weeks, the interventions in the ‘toolkit’ were
psychological techniques to facilitate behaviour change:
• all patients were encouraged to select a contingency management programme offering
shopping vouchers for either good attendance, recovery activities, or abstinence from
drug use;
• additionally, also available were cognitive-behavioural techniques to help cope with
craving and modify disorder-maintaining beliefs or to help alleviate depression; or
• 12-step based therapies to promote attendance at self-help groups; or
• methods to engage partners and families in the treatments.
In a motivational interviewing style, the interventions were usually delivered weekly by
assistant psychologists who received fortnightly individual clinical supervision and weekly
group supervision. The ‘usual’ psychosocial support to which these interventions were
added consisted of fortnightly, half-hour individual appointments with a keyworker for
drug counselling.
Of the 348 patients screened for the study between 2013 and 2015, 273 joined and the
results for 270 were analysed, 135 each assigned to the different treatments. Over 90%
had used non-prescribed opioids in the past four weeks and over 80% crack cocaine.
Typically they had been in treatment for six months (two-thirds on methadone) and were
unemployed men in their late 30s or 40s assessed as dependent on both opioids and
cocaine. The intended end of the trial was 18 weeks after allocation to the treatments
(though another two weeks were allowed if needed), when over 9 in 10 of the patients
who joined the study were still in treatment.
Main findings
About 6 in 10 of the participants allocated to the psychosocial interventions attended over
a third of the scheduled sessions. On average they attended about five of the 12
scheduled sessions and about nine keyworker appointments, while usual-treatment
patients attended 7.5 appointments. Overall retention in treatment did not significantly
differ.
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In the final four weeks of the trial, 16% of those allocated to the psychosocial
interventions were classified as ‘treatment responders’ (no cocaine or heroin use in
past four weeks) compared to just 7% of usual-treatment patients, a statistically
significant difference. Research interviews indicated that during these four weeks,
psychosocial intervention patients spent significantly more days free of opioids
(73% v. 57%) and also of crack cocaine (79% v. 67%); both sets of patients had
only very rarely used powder cocaine. During the same period, work and social
adjustment scores were significantly better in the psychosocial intervention group,
though cognitive function and symptoms of depression or anxiety were about the
same.
Despite the extra costs associated with the interventions (on average just over
£500), patients allocated to the psychosocial interventions imposed a slightly (but
not significantly) lower total cost on society, largely due to substantial but not
significantly lower average costs associated with the crimes they admitted to having
committed during the follow-up period. Use of health and social care services was
broadly similar between the groups, though the psychosocial intervention group
spent more nights in hospital. Their interview responses also indicated that
compared to usual-treatment patients, those allocated to the psychosocial
interventions experienced significantly better health-related quality of life once
missing scores had been estimated.
Across many simulations varying the figures, on the basis of total social costs, even
societies willing to pay very little for an improved response to treatment would
generally find the psychosocial interventions more cost-effective than usual
treatment. Generally too, the psychosocial interventions would gain quality-
adjusted years of life at a cost per year below that considered by NICE to be a
cost-effective use of resources. However, this was not consistently the case when
instead of total costs including those associated with crime, costs were narrowed
down to those imposed on publicly funded health or personal social services, the
perspective recommended by NICE. Then usually the psychosocial interventions
would not gain an extra quality-adjusted year below a cost-effectiveness threshold
of £20,000 per year, and would be only slightly more likely to be cost-effective than
usual treatment if the threshold was moved up to £30,000.
The authors’ conclusions
Compared to typical treatment, at a routine NHS clinic with patients sifted through
minimal exclusion criteria, a team approach with supervised psychology assistants
delivering psychosocial interventions tailored to the individual was found both
effective and cost-effective at reducing illegal drug use among patients not
responding fully to treatment, and a good investment for improving health-related
quality of life. While it may not be advisable to offer standardised psychosocial
interventions across the board, offering more personalised interventions to patients
not responding as desired to treatment seems a more fruitful strategy. That
patients can be motivated to engage in a psychosocial intervention was reflected in
the proportion (59%) who attended at least a third of the sessions.
Practice implications are that clinicians providing opioid maintenance treatment
should assess their patients’ response early once the maintenance dose has been
achieved. If therapy is not providing clinical benefit, even a basic case formulation
will help shed light on why and point to an intervention. Much is also probably to be
gained by supplementing usual assessments with standard clinical interview
schedules and questionnaires, which provide actionable information and inform the
process of selecting change methods. Clinicians should bear in mind that patients’
personal preferences are key. Having a ‘toolbox’ of psychological methods for
promoting change gives flexibility and the ability to adapt treatment according to
assessments and patients’ responses.
 COMMENTARY Adding to an evidence base which only patchily
supports intensifying psychosocial support in methadone and allied maintenance
programmes, the study suggests that it was not the general thesis that was
mistaken, but its implementation in the form of inflexible programmes insufficiently
tailored to patients’ preferences and needs. Take steps to gather the required
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information from the patient on their psychological profile, preferences and
needs, use this to formulate an understanding of their drug use, develop
hypotheses about changing behaviour to be tested using evidence-based
practices, keep adapting as necessary, and the desired improvements emerge
– a strategy in line with current thinking on psychotherapy in general.
The study seems to take us a step further along the road away from a usually
inconclusive horse-race competition between ‘brand name’ therapies, towards
identifying which mix of a variety of psychosocial active ingredients (the
‘toolbox’) work best for which patients (1 2). There is, however, another
possible interpretation of what drove the outcome improvements. All the
patients were encouraged to opt for a variety of contingency management
programme, rewarding them with shopping vouchers for engagement or
abstinence. Instead of the right therapeutic mix, it could be that the findings
primarily represent the well-known effects of these programmes. If that was
the case, any gains might well have been found to have evaporated had the
trial continued beyond the time when the rewards were on offer, a typical
finding in longer term evaluations of contingency management programmes.
Other suggestions from the study are that for the sake of economy – and
perhaps also to avoid upsetting a stable apple cart – this extra effort can be
restricted to patients not already doing well with more basic care, and that a
collaborative approach affording patients a degree of control over the
interventions leads to acceptable levels of engagement. These are important
implications from a groundbreaking study which seems to point one way
towards to a more recovery-oriented opioid maintenance system, in line both
with national policy and clinical opinion.
Though in the featured study the interventions and the system to guide and
adapt them were structured and may to many drug workers have been
unfamiliar, the researchers’ practice recommendations were more modest and
manageable. Effectively they amounted to advice that clinicians keep tabs on
how their patients are doing, try to find out why some are not doing as well
as desired, and then adapt treatment to these assessments bearing in mind
the patient’s preferences. It might be thought that any service which fails to
do this is not just failing to provide optimal care, but failing even to provide
what in any medical sector would be considered minimally acceptable care.
Additional and apparently more optional recommendations are that the
assessments use standard clinical interviews or questionnaires or other
validated methods, and that the adaptations to treatment be selected from a
toolbox of validated psychological change methods.
Delivered in the study by assistant psychologists rather than qualified clinical
psychologists, an attractive aspect to the toolbox approach is that the
constituent skills could readily be disseminated (through training,
monitoring, supervision, ongoing evaluation) across different professional
groups, especially keyworkers, the backbone of addictions support and
treatment, embedded within the familiar motivational interviewing
counselling style. While the therapy is actually happening, the study offers
ways to assess its quality and whether it needs adapting, including a very
brief scale recording the patient’s rating of their therapeutic alliance with the
therapist.
Despite this potential, the modesty of the practice recommendations may be
a recognition of the current low capacity of opioid maintenance programmes
in the UK to systematically implement psychosocial therapies even of a more
basic kind than trialled in the study. Among a UK-wide sample of patients
prescribed medications for opioid dependence in 2011, 40% said they were
not even receiving keyworking or group work. The study’s findings offer
encouragement for services to try to improve on this and for commissioners
to fund these attempts, but these findings emerged from a trial conducted
with greater resources and expertise and perhaps too conducted in a more
promising clinical setting than typically available. They show what can be
achieved by this extra effort, not what will be in more typical circumstances.
Even then, the extra gains in patient welfare may be considered too modest
to warrant the expenditure. These issues are explored further below.
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Is it a good enough investment?
Selecting patients who have used non-prescribed opioids or cocaine in
the past 28 days would exclude only a minority, even of those already
in treatment for six months. On this basis, the treatments trialled in
the study requiring trained staff would be offered to most patients,
transforming medication-based treatments into ones substantially
based on psychosocial therapies. Despite the cost-effectiveness
findings, there must be considerable doubt over whether such an
investment is likely in the foreseeable future.
When as recommended by NICE, the focus is narrowed to costs borne
by the health and personal social services sectors which would provide
the therapies, the featured study did not show they would be
considered a good investment in terms of the standard yardstick of
improving and extending life for the patients. (Though this was
narrowly assessed in health terms, not other quality-of-life
components which might have been more responsive to psychological
therapy such as loneliness, intimacy, interpersonal or family conflict,
social support, and communication.) Only when wider social costs –
especially those associated with crime – were included did
supplementing opioid maintenance with personalised psychosocial
interventions meet criteria for a cost-effective use of resources. The
costs of crime which yielded this result are likely to have been related
to acquisitive crimes committed to be able to purchase heroin or crack
cocaine. Since use of these drugs was reduced by supplementing
treatment with psychosocial therapies, it seems the costs of associated
crime too were reduced. However, there is a strong argument that the
main cost element of these acquisitive crimes – money or goods stolen
or defrauded – should not be included in the calculations, since society
as a whole (including individuals who gain from crime) suffers no net
loss.
There also seems a question over whether interventions were fully
costed in. An appendix detailing these costs makes no mention of the
costs of data collection by researchers used not only for research
purposes, but also to inform the interventions. Not only would these
have added to costs, but they may also have improved outcomes, yet
not be routinely available. The researchers themselves thought “much
is to be gained from the use of clinical scales, which provide actionable
information and inform the process of selecting change methods” –
information provided to clinicians by the researchers. Additionally, the
expertise and experience of the nationally prominent addiction
psychologists on the research team who provided clinical supervision
and attended case conferences cannot be assumed to be replicated
locally.
In seeking to justify these expenditures, services and commissioners
may want to know not just whether the interventions they buy are
more effective than routine care, but also more effective than simply
increasing patient-clinician contact time without introducing the
expertise, interventions and case conferences of the tested
interventions. This question cannot be answered by the study. Other
studies provide some evidence that contact time can matter, but also
that the quality of extra psychosocial inputs can be decisive.
Difficulties in recruiting patients to the study, and a record of fewer
than half the intervention sessions attended by those who did join,
suggest a less than enthusiastic reception by many patients.
Nevertheless, to the research team attendance levels signified a good
level of engagement with the interventions, one which may partly
have been due to the self-selected nature of the patients. Instead of
the intended 368, the study had to make do with 273 because “we
overestimated the number of patients who would be interested in
taking part”. Since their core treatment was not at risk from declining
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to join the study, it seems possible that patients particularly
interested in engaging in the interventions or controlling their
‘on-top’ substance use joined, perhaps not typical of those still
using heroin or cocaine. In some treatment settings, excluding
suicidal patients, those with unresolved medical conditions, or
those facing a possible spell in prison, would exclude an
appreciable portion of the caseload. Had the interventions been
routinely applied across the full range of the still-using caseload,
the results might not have differed.
If the patients were selected, so too was the single clinic at
which the study was conducted, a community clinic associated
with the UK’s leading clinical and research addictions centre at
King’s College London. When an attempt was made to trial
cognitive-behavioural therapy at a broader cross-section of
English methadone clinics, it foundered partly because the
services were overstretched and understaffed and suffered from
high staff turnover. Very few staff had been trained in
psychological interventions and sometimes even basic individual
client keyworking was extremely limited. Just 60 of 369 eligible
patients joined the study and typically they attended just four of
the 24 extra therapy sessions on offer. Difficulties in engaging
clients in the study were attributed partly to a low level of
psychological interventions in services, which in turn led to low
expectations of clients engaging with these interventions.
Worryingly, the researchers discerned a “nihilistic view of
psychological intervention and clients’ capacity for change
among some staff”. Despite implementation problems, this
randomised trial study did find that cognitive-behavioural
therapy was associated with reductions in the severity of
addiction and heroin use and improved compliance with
prescribed methadone, though none of the findings were
statistically significant, so chance fluctuations could not be ruled
out.
A commentary on the featured study raised the issue of whether
average medication doses higher than those in the study might
have left less scope for extra therapy to further reduce heroin
and cocaine use. Recommended methadone and buprenorphine
dose ranges in the UK are respectively 60–120 mg and
12–16 mg a day, though some patients will need more. In the
featured study doses of methadone averaged around 57 mg and
of buprenorphine 11.5 mg, both slightly lower than the
recommended minimum, meaning many patients must have
been prescribed less than recommended.
Guidelines insist on psychosocial support
Notwithstanding patchy evidential support, in many treatment
systems across the world psychosocial support is considered
indispensable for opioid-addicted patients prescribed heroin
substitutes like methadone and buprenorphine. Guidelines insist
that “psychosocial interventions are … a crucial part” of opioid
substitution treatment, and regular counselling may be required
by the regulations governing the programmes. In their title
(Guidelines for the psychosocially assisted pharmacological
treatment of opioid dependence), World Health Organization
guidelines integrally partner the medication component of the
treatment of opioid dependence with what the text recommends
should be “comprehensive psychosocial support to every
patient”. Published in 2017, the UK’s own clinical guidelines on
treatment for substance use problems also insist that in opioid
substitute prescribing programmes, “optimal behaviour change is
unlikely without a good therapeutic alliance and suitable
psychosocial interventions” and that “Treatment for drug misuse
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should always involve a psychosocial component to help
support an individual’s recovery.” The advice is definite,
even if implementation seems to lag a long way behind.
Thanks for their comments on this entry to research author Luke
Mitcheson, Consultant Clinical Psychologist and Head of Addictions
Psychology and Lead Psychologist for Lambeth Addictions at the South
London and Maudsley NHS Foundation Trust in England, and Kevin
Ducray, Senior Clinical Psychologist at the Health Service Executive
National Drug Treatment Centre in Ireland. Commentators bear no
responsibility for the text including the interpretations and any
remaining errors.
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